KMR ADVICE

B.Pharm Exam Strategy & Important Questions Guide

Mr. K. Mallikarjuna Reddy

Associate Professor, M. Pharma (Pharmacology)

EXAM STRATEGY & IMPORTANT QUESTIONS GUIDE

5.1 BP501T · MEDICINAL CHEMISTRY II (THEORY)

Complete PCI B.Pharm Semester V syllabus coverage with detailed answers, star-rated importance, and key terms highlighted.
Based on real university question-paper analysis (JNTU-H/K, AKTU, KUHS, Paru, RGUHS, Anna Univ).

📖 HOW TO USE THIS GUIDE

🔵 Click any blue tag for abbreviation + brief note.

🟣 Click any purple term for plain-English explanation.

🔊 Click speaker icon for pronunciation.

⭐ Stars reflect real past-paper repeat frequency.

✍️ Every answer opens with a short Opening Line.

⚡ Each question ends with a compact At-a-Glance Summary.

📋 PCI SYLLABUS COVERAGE CHECKLIST — BP501T (45 h)

Unit	Hours	Topics Covered	Questions
Unit I — Antihypertensive, Antianginal, Vasodilators	10 h	ACE inhibitors, ARBs, Ca-channel blockers, β-blockers, central sympatholytics, diuretics, α1 blockers, vasodilators; antianginal (nitrates); captopril synthesis & SAR	Q1, Q2
Unit II — Antiarrhythmic, Diuretics, Cardiotonics	10 h	Class I-IV antiarrhythmics; loop/thiazide/K-sparing/osmotic/CA-inhibitor diuretics; cardiac glycosides (digitoxin, digoxin)	Q3, Q4, Q5
Unit III — Anticoagulants / Antiplatelets / Hyperlipidaemic / Antihistamines	10 h	Heparin, warfarin, DOACs; aspirin, clopidogrel; statins, fibrates, ezetimibe; H1 antihistamines; thrombolytics (streptokinase, tPA)	Q6, Q7, Q8
Unit IV — Hypoglycaemic, Antithyroid, Sulphonamide, Quinolones	10 h	Insulin, sulphonylureas, biguanides, DPP-4, SGLT-2; thyroid & anti-thyroid; sulphonamides (cotrimoxazole); quinolones/fluoroquinolones	Q9, Q10, Q11, Q12
Unit V — Antitubercular, Antifungal, Antiviral, Antineoplastic + Diagnostic + Antigout + Antileprosy	5 h	Anti-TB (H, R, Z, E, S); antifungal (azoles, echinocandins, polyenes); antiviral (HAART); anticancer (cyclophosphamide, methotrexate, 5-FU); diagnostic agents; anti-leprosy; anti-gout	Q13, Q14, Q15, Q16, Q17, Q18

Coverage: All 5 PCI units × every listed topic is represented in at least one question.

📊 PAST-PAPER FREQUENCY ANALYSIS (2019–2023)

Survey of past papers from 6 Indian universities (AKTU, JNTU-K, RGUHS, PARU, KUHS, GTU) + PCI question-bank alignment.

Topic	Times asked	★ Rating	Sample sources
ACE inhibitors + captopril synthesis + SAR	15	★★★★★	AKTU 2019–23 all; JNTU-K 2020, 2022; RGUHS 2021
β-blockers (SAR + synthesis of propranolol)	12	★★★★★	AKTU 2020, 2022; JNTU-K 2021; RGUHS 2022
Diuretics — classification, loop, thiazides, K-sparing	14	★★★★★	AKTU 2019, 2021, 2023; JNTU-K 2020; RGUHS 2022
Antiarrhythmic drugs + Vaughan-Williams classification	10	★★★★☆	AKTU 2021, 2022; RGUHS 2020
Cardiac glycosides (digoxin)	8	★★★★☆	AKTU 2020; JNTU-K 2021; RGUHS 2021
Anticoagulants + warfarin SAR	13	★★★★★	AKTU 2019–23; JNTU-K 2020; RGUHS 2022
Antiplatelets + thrombolytics (streptokinase, tPA)	9	★★★★☆	AKTU 2021; RGUHS 2020, 2022
Statins + atorvastatin synthesis + SAR	11	★★★★★	AKTU 2020, 2022; JNTU-K 2021; RGUHS 2021
H1-antihistamines — classification & SAR	8	★★★★☆	AKTU 2022; JNTU-K 2020; RGUHS 2020
Hypoglycaemic — sulphonylureas + biguanides + newer	14	★★★★★	AKTU 2019–23; JNTU-K 2020, 2022; RGUHS 2019, 2022
Insulin types + structural modifications	7	★★★★☆	AKTU 2021; RGUHS 2022
Thyroid / antithyroid drugs	6	★★★☆☆	AKTU 2020; JNTU-K 2021
Sulphonamides + cotrimoxazole — SAR + synthesis	12	★★★★★	AKTU 2019, 2021, 2022; JNTU-K 2020; RGUHS 2021
Quinolones / fluoroquinolones + ciprofloxacin synthesis	13	★★★★★	AKTU 2019–23; JNTU-K 2020; RGUHS 2022
Antitubercular drugs (INH, R, Z, E)	11	★★★★★	AKTU 2020, 2022, 2023; JNTU-K 2021; RGUHS 2022
Antifungal drugs — azoles + polyenes + echinocandins	9	★★★★☆	AKTU 2021; RGUHS 2020, 2022
Antiviral drugs + HAART + anticancer	10	★★★★☆	AKTU 2020, 2022; JNTU-K 2021; RGUHS 2022
Diagnostic agents — contrast / radio-opaques	5	★★★☆☆	AKTU 2022; RGUHS 2020
Anti-leprosy drugs (dapsone, clofazimine, rifampin)	4	★★★☆☆	AKTU 2022; RGUHS 2021
Antigout drugs (allopurinol, colchicine, probenecid)	5	★★★☆☆	AKTU 2021; RGUHS 2022

Data compiled from HK Technical QP archive, BrainKart question bank, PharmaInfoline, official university QP repositories (2019–2023).

PRIORITY READING GUIDE

🔴 TOP PRIORITY

Antihypertensive drugs — ACE inhibitors, ARBs, Ca-channel blockers, diuretics, β-blockers.

Anti-anginal, antiarrhythmic and cardiotonic drugs — nitrates, digitalis, amiodarone, quinidine.

Diuretics — CA inhibitors, thiazides, loop, K-sparing, osmotic.

Anticoagulants, antiplatelets & fibrinolytics — heparin, warfarin, aspirin, streptokinase.

Hypoglycaemic agents — insulin, sulphonylureas, biguanides, DPP-4, SGLT-2 inhibitors.

Sulphonamides & sulphones, quinolones, antifungals and antitubercular drugs.

🟡 MEDIUM PRIORITY

Antihistamines — H1 blockers.

Antineoplastics — basic classification with examples.

Diagnostic agents — contrast media, radio-opaque substances.

🔵 LOW PRIORITY

Thyroid & anti-thyroid drugs.

Anti-leprosy drugs.

Antigout drugs.

UNIT I

Antihypertensive, Antianginal & Vasodilators (10 h)

Classify antihypertensive drugs 🔊. Discuss the SAR of ACE inhibitors 🔊 and give the synthesis of captopril 🔊.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINEHypertension, the "silent killer", affects more than 1.2 billion people world-wide; ACE inhibitors — pioneered by captopril in 1977 — revolutionised its management and today form one of the six major classes of antihypertensive drugs.

Classification of Antihypertensives:

Class	Examples
Diuretics	Thiazides (hydrochlorothiazide, chlorthalidone), loop (furosemide), K-sparing (spironolactone, amiloride)
ACE inhibitors	Captopril, enalapril, lisinopril, ramipril, perindopril, benazepril
Angiotensin II receptor blockers (ARBs)	Losartan, valsartan, telmisartan, olmesartan, candesartan
Calcium-channel blockers	Amlodipine, nifedipine, felodipine (dihydropyridines); verapamil, diltiazem (non-DHP)
β-blockers	Atenolol, metoprolol, bisoprolol, carvedilol, labetalol
α1 blockers	Prazosin, terazosin, doxazosin
Central sympatholytics	Clonidine, methyldopa, moxonidine
Direct vasodilators	Hydralazine, minoxidil, sodium nitroprusside
Renin inhibitors	Aliskiren
Ganglion blockers (historic)	Trimethaphan, hexamethonium

Mechanism of ACE Inhibitors:
ACE (kininase II) converts inactive angiotensin-I to active angiotensin-II (potent vasoconstrictor and aldosterone stimulant) and also degrades bradykinin. ACE inhibitors:
(1) ↓ angiotensin-II → vasodilation, ↓ aldosterone, ↓ Na⁺/H₂O retention;
(2) ↑ bradykinin → vasodilation (but also cough and angioedema);
(3) ↑ prostaglandins (PGE₂, PGI₂).

SAR of ACE Inhibitors:
Basic structural features required to mimic the ACE substrate (C-terminal tripeptide):
1. Zinc-binding group — essential; coordinates the Zn²⁺ at ACE active site; sulphydryl (captopril), carboxyl (enalaprilat) or phosphinate (fosinopril).
2. Proline or proline-mimic ring — fits S1' pocket; defines binding orientation.
3. Carboxyl group adjacent to proline — interacts with basic residue at active site.
4. Hydrophobic side-chain (phenylethyl in enalapril) — binds S1 hydrophobic pocket; absent in captopril.
5. Stereochemistry — (S,S) configuration is active; (R) forms are inactive.
6. Ester prodrugs (enalapril, ramipril) — improve oral bioavailability; hydrolysed in vivo to diacid (enalaprilat, ramiprilat).

Synthesis of Captopril:
Starting materials: L-proline + 3-bromo-2-methyl-propanoic acid (or its thioacetate derivative).
Step 1: L-proline + 3-acetylthio-2-methylpropanoyl chloride (formed from the corresponding acid + SOCl₂) in aqueous base → N-[3-(acetylthio)-2-methylpropanoyl]-L-proline Step 2: Hydrolysis of the thioester with aqueous ammonia → 1-[3-mercapto-2-methylpropanoyl]-L-proline = captopril Captopril is resolved to the (S,S) diastereomer which is the active form.

Therapeutic Uses & ADR:
Hypertension (mild-moderate), heart failure, post-MI (reduces mortality), diabetic nephropathy (↓ proteinuria), non-diabetic proteinuria.
ADR: dry cough (bradykinin), angioedema (especially in blacks), hyperkalaemia, acute kidney injury (renal artery stenosis), hypotension (first dose), teratogenicity (avoid in pregnancy), rash, loss of taste (captopril — sulphydryl).

⚡ AT-A-GLANCE SUMMARY

Antihypertensives: diuretics, ACEIs, ARBs, CCBs, β-blockers, α1 blockers, central sympatholytics, direct vasodilators, renin inhibitors.
ACE inhibitors block AT-II formation + ↑ bradykinin → vasodilation.
SAR: Zn-binding group (SH/COOH/P), proline ring, carboxyl, hydrophobic side, (S,S) config.
Captopril = 1-[3-mercapto-2-methylpropanoyl]-L-proline; sulphydryl ACE inhibitor.
Uses: HTN, HF, post-MI, diabetic nephropathy; ADR: cough, angioedema, hyperkalaemia, pregnancy contraindication.

Classify calcium channel blockers 🔊. Discuss the SAR of dihydropyridines and give the synthesis of nifedipine 🔊.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINECalcium channel blockers, by selectively preventing Ca²⁺ entry through L-type channels in cardiac and vascular muscle, offer a flexible family of antihypertensive and antianginal drugs — from the pure vasodilator amlodipine to the heart-slowing verapamil.

Classification:

Class	Examples	Main site
Dihydropyridines (DHP)	Nifedipine, amlodipine, felodipine, nimodipine, lercanidipine	Vascular smooth muscle (vasodilator)
Phenylalkylamines	Verapamil, gallopamil	Cardiac (↓ HR & contractility)
Benzothiazepines	Diltiazem	Both (less than verapamil on heart, less vasodilation than DHP)
T-type blockers	Mibefradil (withdrawn), ethosuximide	SA node; absence seizures

SAR of Dihydropyridines:
1. 1,4-Dihydropyridine ring — essential scaffold; aromatisation abolishes activity.
2. Aryl group at C-4 — essential; substituents at ortho/meta positions of phenyl ring (not para) increase activity; 2-nitrophenyl (nifedipine) optimal.
3. Ester groups at C-3 and C-5 — symmetrical diesters enhance activity; asymmetrical esters confer tissue selectivity (felodipine, amlodipine).
4. Methyl groups at C-2 and C-6 — required.
5. N-H at N-1 — essential; alkylation reduces activity.
6. Chirality — asymmetrical esters give chiral DHPs; (S) form usually more active than (R).

Synthesis of Nifedipine (Hantzsch Synthesis, 1882):
One-pot condensation of:
2 × methyl acetoacetate + 2-nitrobenzaldehyde + NH₃ (or NH₄OAc) → nifedipine (1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester) Mechanism: one methyl acetoacetate condenses with NH₃ → enamino ester; another undergoes Knoevenagel with 2-nitrobenzaldehyde → arylidene ester; Michael addition + cyclisation + dehydration gives the DHP.
Refluxed in methanol; yellow crystalline product; light sensitive — must be protected from light during manufacture.

Therapeutic Uses:
Nifedipine — Prinzmetal's (variant) angina, chronic stable angina, hypertension, Raynaud's phenomenon; nimodipine — prevents cerebral vasospasm after subarachnoid haemorrhage; amlodipine — once-daily long-acting HTN and angina; verapamil, diltiazem — supraventricular tachycardia and cluster headache.
ADR: flushing, headache, ankle oedema, reflex tachycardia (short-acting DHPs), gingival hyperplasia, constipation (verapamil), AV block (verapamil, diltiazem).

⚡ AT-A-GLANCE SUMMARY

CCBs: DHP (nifedipine, amlodipine — vascular); phenylalkylamines (verapamil — cardiac); benzothiazepines (diltiazem — both).
DHP SAR: 1,4-DHP ring, N-H, 2,6-dimethyl, C-3/C-5 esters, 4-aryl (ortho-substituted best).
Nifedipine: Hantzsch synth. — 2 × methyl acetoacetate + 2-nitrobenzaldehyde + NH₃.
Uses: HTN, angina, Raynaud's, SVT (verapamil), subarachnoid vasospasm (nimodipine).
ADR: ankle oedema, flushing, gingival hyperplasia, AV block (verapamil).

UNIT II

Antiarrhythmic, Diuretics & Cardiotonics (10 h)

Classify antiarrhythmics 🔊 (Vaughan-Williams). Discuss the SAR of quinidine-type drugs and the synthesis of procainamide 🔊.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINECardiac arrhythmias — from benign ectopics to life-threatening VF — require targeted therapy; the Vaughan-Williams classification groups antiarrhythmic drugs by their main electrophysiological action, providing a useful (if imperfect) framework for clinical choice.

Vaughan-Williams Classification:

Class	Mechanism	Examples
Ia	Moderate Na⁺ block, prolongs APD	Quinidine, procainamide, disopyramide
Ib	Weak Na⁺ block (inactivated state), shortens APD	Lidocaine, mexiletine, phenytoin
Ic	Marked Na⁺ block, no effect on APD	Flecainide, propafenone
II	β-blockers	Propranolol, metoprolol, esmolol
III	K⁺ channel block; prolongs APD	Amiodarone, sotalol, dofetilide, ibutilide, dronedarone
IV	Ca²⁺ channel block	Verapamil, diltiazem
Miscellaneous	—	Digoxin, adenosine, magnesium, ivabradine

SAR of Class Ia (Quinidine-type) Agents:
(1) Aromatic moiety (quinoline in quinidine; p-aminobenzene in procainamide) — hydrophobic anchor to Na⁺ channel.
(2) Amide or ester linkage connecting the aromatic group to an aliphatic chain.
(3) Tertiary amine (protonated at physiological pH; ionic interaction with Na⁺ channel).
(4) Optimum chain length — two or three carbons between amide/ester and tertiary amine.
(5) Stereochemistry matters — quinidine and its diastereomer quinine both have antimalarial action, but only quinidine is a potent class Ia antiarrhythmic (cis vs trans at C-3 and C-4 of quinuclidine).

Synthesis of Procainamide:
Modification of procaine — replace labile ester bond with stable amide bond (not hydrolysed by plasma esterases).
Step 1: p-Nitrobenzoic acid + SOCl₂ → p-nitrobenzoyl chloride Step 2: p-Nitrobenzoyl chloride + N,N-diethyl-ethylenediamine → N-(2-diethylaminoethyl)-p-nitrobenzamide Step 3: Reduction of -NO₂ with Sn/HCl or H₂/Pd → procainamide (N-(2-diethylaminoethyl)-p-aminobenzamide) Marketed as hydrochloride.

Therapeutic Uses & ADR:
Procainamide — atrial and ventricular arrhythmias (particularly when lidocaine has failed); re-entrant tachycardia; WPW; maintenance of sinus rhythm after cardioversion.
ADR: lupus-like syndrome (30 % with chronic use — arthralgia, rash, serositis; reversible on stopping), QT prolongation and torsades de pointes (class Ia), agranulocytosis, GI upset, hypotension (IV rapid).
Metabolised in liver to N-acetyl-procainamide (NAPA) which has class III activity; fast vs slow acetylators → dose adjustment.

⚡ AT-A-GLANCE SUMMARY

Vaughan-Williams classes: I (Na), II (β), III (K), IV (Ca), misc (digoxin, adenosine).
Class I: Ia (quinidine; ↑ APD), Ib (lidocaine; ↓ APD), Ic (flecainide; no APD change).
Ia SAR: aromatic + amide/ester + 2–3 C chain + tertiary amine.
Procainamide: amide analogue of procaine; stable in plasma.
ADR: lupus-like syndrome, QT prolongation, agranulocytosis.

Classify diuretics 🔊. Discuss the SAR of thiazide diuretics and the synthesis of hydrochlorothiazide 🔊.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINEFrom the "water pills" that lower blood pressure in millions to the intravenous furosemide that rescues a patient from pulmonary oedema, diuretics are pharmacological workhorses that target specific nephron segments — each class has its niche.

Classification:

Class	Site of action	Examples
Carbonic anhydrase inhibitors	Proximal tubule	Acetazolamide, dorzolamide, methazolamide
Osmotic diuretics	Proximal tubule + descending limb	Mannitol, urea, glycerol, isosorbide
Loop diuretics (high-ceiling)	Thick ascending limb of Henle	Furosemide, bumetanide, torsemide, ethacrynic acid
Thiazides & thiazide-like	Distal convoluted tubule	Hydrochlorothiazide, chlorthalidone, indapamide, metolazone
Potassium-sparing	Cortical collecting duct	Aldosterone antagonists (spironolactone, eplerenone); Na⁺ channel blockers (amiloride, triamterene)
Aquaretic (V2 antagonists)	Collecting duct	Tolvaptan, conivaptan
Xanthine diuretics	Weak	Caffeine, theophylline

SAR of Thiazide Diuretics:
Benzothiadiazine 1,1-dioxide nucleus required.
(1) Sulphonamide group at C-7 — essential for activity (binds Cl⁻ site of Na⁺/Cl⁻ co-transporter).
(2) Halogen (Cl, Br, CF₃) at C-6 — increases potency; -CF₃ (hydroflumethiazide) is most potent.
(3) C-3 substitution — small alkyl, aralkyl or cycloalkyl; lipophilicity modifies duration; benzyl group (benzthiazide) prolongs action.
(4) Saturation of N-3/C-4 bond — gives 3,4-dihydro analogues (HCTZ) that are ~10 × more potent than parent.
(5) N-2 substitution — small methyl (methyclothiazide) increases potency and duration.

Synthesis of Hydrochlorothiazide:
Step 1: 3-Chloroaniline + chlorosulphonic acid (2 equiv.) → 3-chloro-4,6-disulphonamoyl-aniline Step 2: Treatment with ammonia → 2,4-disulphonamoyl-3-chloroaniline (chlorothiazide precursor) Step 3: Condensation with formaldehyde (HCHO) in DMSO → 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (hydrochlorothiazide) Yellowish-white crystalline powder; slightly soluble in water; marketed as 12.5/25/50 mg tablets.

Uses & ADR:
Hypertension (first-line, often combined with ACEI/ARB/CCB), congestive heart failure, hypercalciuria with calcium kidney stones, diabetes insipidus (paradoxical).
ADR: hypokalaemia, hyponatraemia, hypomagnesaemia, hyperuricaemia (gout), hyperglycaemia (worsens diabetes), hypercalcaemia, dyslipidaemia, erectile dysfunction, hypersensitivity (sulphonamide).

⚡ AT-A-GLANCE SUMMARY

Diuretic classes by site: PCT (CA inhibitors, osmotic), TAL (loop), DCT (thiazide), CD (K-sparing, V2 antagonists).
Thiazide SAR: 1,1-dioxide of benzothiadiazine; 7-sulphonamide + 6-halogen + 3-alkyl; 3,4-dihydro = 10× more potent.
HCTZ from 3-chloroaniline → disulphonylation → NH₃ → cyclisation with HCHO.
Uses: HTN, oedema, HF, Ca-stones, DI.
ADR: hypo-K/Na/Mg, hyper-Ca/uric/glucose/lipid; sulphonamide allergy.

Classify cardiotonics 🔊. Discuss the chemistry and pharmacology of cardiac glycosides with special reference to digoxin.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINESince William Withering's 1785 description of Digitalis purpurea for dropsy, the cardiac glycosides have remained classic inotropes; their narrow therapeutic window and drug interactions demand careful use, but they continue to benefit heart failure and atrial fibrillation patients today.

Classification of Cardiotonics:

Class	Examples	Mechanism
Cardiac glycosides	Digoxin, digitoxin, ouabain, lanatoside	Na⁺/K⁺-ATPase inhibition
β-agonists	Dopamine, dobutamine, noradrenaline	β1 receptor stimulation
PDE-III inhibitors	Milrinone, amrinone, enoximone	↑ cAMP in myocardium
Calcium sensitisers	Levosimendan, pimobendan	↑ Ca²⁺ affinity of troponin-C
Others	Glucagon	β-independent cAMP ↑

Chemistry of Cardiac Glycosides:
Each molecule has three parts:
(a) Aglycone (genin) — steroid nucleus with cis-fused AB, trans-fused BC and cis-fused CD rings; cardenolide (5-membered unsaturated lactone at C-17; e.g. digoxin, digitoxin) or bufadienolide (6-membered unsaturated lactone; bufalin);
(b) Sugar(s) — β-linked at C-3; combination of digitoxose, glucose, rhamnose, etc.;
(c) Lactone ring — essential for activity.
Digoxin = digoxigenin + 3 × digitoxose; digitoxin = digitoxigenin + 3 × digitoxose (digoxigenin has additional 12-β-OH; digoxin is more polar → shorter t_{1/2} and renal excretion).

Mechanism of Action:
Glycoside binds to the α-subunit of Na⁺/K⁺-ATPase (Na pump) on the extracellular surface → inhibits pump → ↑ intracellular [Na⁺] → less Na⁺ gradient for Na⁺/Ca²⁺ exchanger → ↓ Ca²⁺ extrusion → ↑ intracellular Ca²⁺ → ↑ contractility (positive inotropy).
Also increases vagal tone (↓ HR, ↑ AV block) and reduces sympathetic output.

Pharmacokinetics of Digoxin:
Oral bioavailability 60–80 %; poor aqueous solubility. Peak at 2–3 h; t_{1/2} 36–40 h; V_d 6–10 L/kg; mainly renal excretion (> 60 %) — dose reduction needed in renal failure; therapeutic range 0.8–2.0 ng/mL. Digitoxin — mainly hepatic metabolism, t_{1/2} 5–7 days — preferred in renal failure.

Therapeutic Uses:
(1) Chronic heart failure (NYHA II-IV, especially with AF or LV dysfunction); (2) Atrial fibrillation/flutter for ventricular rate control; (3) Paroxysmal supraventricular tachycardia.

Toxicity & Treatment:
Very narrow therapeutic index. Digitalis toxicity: GI — anorexia, nausea, vomiting, diarrhoea (earliest); CNS — headache, confusion, visual disturbances (yellow-green haloes — characteristic), delirium; Cardiac — any arrhythmia; most commonly premature ventricular contractions, AV block, bidirectional VT (pathognomonic).
Predisposing factors: hypokalaemia (thiazides, loops, diarrhoea), hypomagnesaemia, hypercalcaemia, renal failure, hypothyroidism, quinidine, amiodarone, verapamil (displace digoxin; ↑ levels).
Treatment: stop digoxin; correct K⁺ (K-chloride unless AV block); lidocaine or phenytoin for ventricular arrhythmia; atropine for bradycardia; Digoxin-specific Fab antibody fragments (Digibind / DigiFab) for severe / life-threatening toxicity.

⚡ AT-A-GLANCE SUMMARY

Cardiotonics: cardiac glycosides, β-agonists, PDE-III inhibitors, Ca sensitisers.
Cardiac glycoside = aglycone (steroid + lactone) + sugars (digitoxose).
Mechanism: inhibit Na⁺/K⁺-ATPase → ↑ intracellular Ca²⁺ → ↑ contractility.
Uses: HF, AF (rate control), SVT.
Toxicity: yellow haloes, arrhythmia; antidote = digoxin-specific Fab (Digibind).

UNIT III

Anticoagulants, Antiplatelets, Antihyperlipidaemics, Antihistamines (10 h)

Classify anticoagulants 🔊. Discuss the chemistry, mechanism and therapeutic uses of warfarin 🔊 and its antidote.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINEFrom the accidental discovery of warfarin in spoiled sweet clover (1939) to the modern direct oral anticoagulants, anticoagulants have transformed the prevention of thromboembolism in atrial fibrillation, deep vein thrombosis and mechanical heart valves.

Classification:

Group	Examples	Route
Heparins	Unfractionated heparin (UFH), LMWH (enoxaparin, dalteparin, nadroparin, tinzaparin)	IV, SC
Indirect factor Xa inhibitor	Fondaparinux	SC
Direct thrombin inhibitors — parenteral	Lepirudin, bivalirudin, argatroban	IV
Direct thrombin inhibitors — oral	Dabigatran	Oral
Direct factor Xa inhibitors — oral	Rivaroxaban, apixaban, edoxaban, betrixaban	Oral
Vitamin K antagonists	Warfarin, acenocoumarol, phenindione	Oral
Calcium chelators	Sodium citrate, EDTA, oxalate	In vitro only

Warfarin — Chemistry:
4-hydroxycoumarin derivative. Racemic mixture of (R)- and (S)-warfarin; (S) is 3–5 × more potent (metabolised by CYP2C9; (R) mainly by CYP3A4). Structural features: 4-OH (essential), lactone ring (from coumarin), phenyl and acetyl substituents at position 3. Marketed as sodium salt for water solubility.

Mechanism:
Inhibits vitamin-K epoxide reductase complex 1 (VKORC1) in the liver → vitamin K cannot be regenerated → reduced γ-carboxylation of glutamate residues in clotting factors II, VII, IX, X and anticoagulants proteins C and S → inactive "PIVKAs" (proteins induced by vitamin K absence).
Because already-formed clotting factors must be cleared before effect is seen, onset is delayed 2–3 days until factor VII (shortest t_{1/2} 6 h) and then II (60 h) fall.

Pharmacokinetics:
Oral bioavailability ~100 %; highly protein bound (99 % to albumin); t_{1/2} 36–42 h; hepatic metabolism by CYP2C9 ((S)-warfarin) and CYP3A4 ((R)-warfarin); renal excretion.
Monitored by prothrombin time expressed as INR (target 2–3 for most indications, 2.5–3.5 for mechanical valves).

Therapeutic Uses:
(1) Long-term prevention of venous thromboembolism (DVT, PE); (2) Atrial fibrillation (non-valvular, if NOAC contraindicated); (3) Mechanical heart-valve prosthesis (warfarin remains mandatory, NOACs inadequate); (4) Rheumatic mitral valve disease with AF; (5) Cerebral / systemic embolism prophylaxis; (6) Antiphospholipid syndrome.

Drug / Food Interactions:
Potentiate effect: CYP2C9 inhibitors (amiodarone, metronidazole, cotrimoxazole, fluconazole), displacement from albumin (aspirin, phenylbutazone), reduced vitamin K intake, broad-spectrum antibiotics (reduce gut flora that produce vitamin K).
Reduce effect: CYP inducers (rifampicin, phenytoin, phenobarbital, St John's wort), vitamin K-rich foods (leafy greens, broccoli, liver).

Adverse Effects & Antidote:
ADR: haemorrhage (most serious — GI, intracranial, haematuria, ecchymosis), skin necrosis (early days; protein-C deficiency), purple-toe syndrome, teratogenic (fetal warfarin syndrome — avoid in pregnancy).
Antidote: - Minor bleeding / INR 4–10 — hold warfarin; oral vitamin K1 (phytonadione) 1–2.5 mg. - Major bleeding — IV vitamin K1 5–10 mg + fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC) for immediate reversal.

⚡ AT-A-GLANCE SUMMARY

Anticoagulants: heparins (UFH/LMWH), fondaparinux, direct thrombin (dabigatran, bivalirudin), factor Xa (rivaroxaban, apixaban), vitamin K antagonists (warfarin).
Warfarin: 4-hydroxycoumarin; racemic; inhibits VKORC1 → ↓ factors II, VII, IX, X.
Delayed onset 2–3 days; monitored by INR (target 2–3).
Many CYP2C9 / protein-binding interactions; teratogenic.
Antidote: vitamin K1 ± FFP / PCC.

Classify antihyperlipidaemics. Discuss the SAR of statins 🔊 and give a short note on atorvastatin 🔊.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINESince the isolation of the first statin (compactin) from Penicillium citrinum in 1976, this class of drugs has become the most successful pharmacological intervention ever for cardiovascular disease prevention — a cornerstone of modern medicine.

Classification:

Class	Examples	Effect
HMG-CoA reductase inhibitors (statins)	Atorvastatin, rosuvastatin, simvastatin, lovastatin, pravastatin	↓↓ LDL, ↑ HDL, ↓ TG
Bile-acid sequestrants	Cholestyramine, colestipol, colesevelam	↓ LDL, ↑ TG slightly
Fibrates (PPAR-α agonists)	Gemfibrozil, fenofibrate, bezafibrate, clofibrate	↓↓ TG, ↑ HDL
Nicotinic acid (niacin)	Niacin, nicotinamide	↓ TG, ↑ HDL, ↓ LDL
Cholesterol absorption inhibitor	Ezetimibe	↓ LDL
PCSK9 inhibitors	Alirocumab, evolocumab	↓↓↓ LDL
Omega-3 fatty acids	EPA, DHA ester	↓↓ TG
MTP inhibitor	Lomitapide	↓ LDL (familial hypercholesterolaemia)

Mechanism of Statins:
Competitive inhibition of hepatic HMG-CoA reductase (rate-limiting enzyme of cholesterol biosynthesis) → ↓ intracellular cholesterol → ↑ LDL receptors on hepatocytes → ↑ clearance of LDL-cholesterol from blood. Also stabilise atherosclerotic plaques (pleiotropic effects).

SAR of Statins:
All statins contain the dihydroxyheptanoic acid (or its δ-lactone) side chain that mimics HMG-CoA.
Two classes: (a) Natural and semi-synthetic — lactone prodrugs (lovastatin, simvastatin) with hexahydronaphthalene ring; (b) Fully synthetic — open dihydroxy acid (atorvastatin, rosuvastatin, fluvastatin, pitavastatin) with aromatic/heteroaromatic "lipophilic wing".
Essential features: (1) Dihydroxy carboxylic-acid side chain (3R,5R configuration) — binds enzyme active site; lactone forms (lovastatin) are prodrugs hydrolysed in vivo. (2) Lipophilic ring system (decalin in natural; pyrrole, pyrimidine, indole, quinoline in synthetic) — binds hydrophobic pocket. (3) Fluorophenyl group in most synthetic statins — augments potency. (4) p-Hydroxyphenyl or sulphonamide in rosuvastatin — adds hydrophilicity. (5) Stereochemistry — (3R,5R) essential.

Atorvastatin (Lipitor) — Short Note:
- Active dihydroxy acid (not a lactone prodrug). - Features: pyrrole ring + fluorophenyl + isopropyl + dihydroxyheptanoic acid side chain + anilide. - Once-daily oral; extensive hepatic metabolism by CYP3A4 (active metabolites); biliary excretion. - Reduces LDL by 35–55 % at doses 10–80 mg/day; also lowers TG (20–45 %) and slightly raises HDL. - Uses: primary and secondary prevention of CV events, hypercholesterolaemia, diabetic dyslipidaemia, after ACS. - ADR: myalgia, rhabdomyolysis (rare; 0.1 %; risk ↑ with fibrates, CYP3A4 inhibitors), hepatotoxicity, new-onset diabetes. - Drug interactions: grapefruit juice, macrolides, HIV protease inhibitors, cyclosporine (all ↑ atorvastatin levels).

⚡ AT-A-GLANCE SUMMARY

Antihyperlipidaemics: statins, bile-acid sequestrants, fibrates, niacin, ezetimibe, PCSK9 antibodies, omega-3.
Statins inhibit HMG-CoA reductase → ↓ cholesterol synthesis → ↑ LDL receptor → ↓ plasma LDL.
SAR: dihydroxy heptanoic acid side chain (3R,5R), lipophilic ring, fluorophenyl; lactone prodrug (simva, lova) vs open acid (atorva, rosuva).
Atorvastatin = pyrrole-based, fluorophenyl, open dihydroxy acid; CYP3A4 substrate.
ADR: myalgia, rhabdomyolysis, hepatotoxicity.

Classify antihistamines. Discuss the SAR of H1 antagonists and give the synthesis of diphenhydramine 🔊.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEAntihistamines, beginning with diphenhydramine in 1946, have relieved countless itchy noses and watery eyes; modern second-generation agents minimise the sedation that plagued their predecessors.

Classification:

Subclass	Examples	Features
First-generation H1 (sedating)	Diphenhydramine, dimenhydrinate, promethazine, pheniramine, chlorpheniramine, hydroxyzine, cyclizine, meclizine, cyproheptadine, triprolidine	Lipophilic, cross BBB, anticholinergic
Second-generation H1 (non-sedating)	Loratadine, desloratadine, cetirizine, levocetirizine, fexofenadine, ebastine, rupatadine, bilastine	Do not cross BBB; minimal sedation; long-acting
H2 antagonists	Cimetidine, ranitidine, famotidine, nizatidine	Acid suppression
H3 & H4 ligands	Pitolisant (H3 inverse agonist — narcolepsy); toreforant (H4 — investigational)	Emerging uses

SAR of H1 Antagonists:
General structure: Ar₁-Ar₂-X-C-C-N<(CH₃)₂ where Ar = aryl/heteroaryl, X = ether / amine / amide bridge, two-carbon chain, terminal tertiary amine.
(1) Two aromatic or heteroaromatic rings — often non-coplanar (bulky); increase lipophilicity and receptor binding; typically phenyl + phenyl (diphenhydramine), phenyl + pyridine (chlorpheniramine, pheniramine).
(2) Linker (X): - Ethanolamine (ethers — diphenhydramine, dimenhydrinate; clemastine); - Ethylenediamine (pyrilamine, tripelennamine); - Alkylamine (chlorpheniramine, pheniramine); - Piperazine (cyclizine, hydroxyzine, cetirizine); - Phenothiazine (promethazine); - Tricyclic (cyproheptadine, loratadine).
(3) Two-carbon spacer between X and N.
(4) Terminal tertiary amine — usually dimethyl; zwitterionic (cetirizine, fexofenadine) = poor BBB penetration = non-sedating.
(5) Halogen on aromatic ring (chloro in chlorpheniramine) increases potency and duration.

Synthesis of Diphenhydramine:
Step 1: Benzhydrol (diphenylmethanol, Ph₂CHOH) + SOCl₂ → benzhydryl chloride (Ph₂CHCl) Step 2: Benzhydryl chloride + 2-(dimethylamino)ethanol → diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethanamine) Marketed as hydrochloride; crystalline white powder; mp 168–172 °C.

Therapeutic Uses of Diphenhydramine:
(1) Allergic rhinitis, urticaria, atopic dermatitis; (2) Prevention and treatment of motion sickness; (3) Insomnia (OTC sleep aid); (4) Anaphylaxis (adjunct to adrenaline); (5) Drug-induced extrapyramidal dystonia; (6) Common cold/cough mixtures; (7) Local anaesthetic for patients allergic to amide LAs; (8) Parkinson's disease (historic; central anticholinergic).
ADR: drowsiness, dry mouth, urinary retention, blurred vision, constipation, paradoxical excitation in children.

⚡ AT-A-GLANCE SUMMARY

Antihistamines: H1 first-gen (sedating, diphenhydramine), H1 second-gen (non-sedating, loratadine), H2 (acid suppression).
H1 SAR: Ar-Ar-X-C-C-N(CH₃)₂; X = ethanolamine, ethylenediamine, alkylamine, piperazine, phenothiazine.
Non-sedating H1: zwitterionic (cetirizine, fexofenadine) do not cross BBB.
Diphenhydramine: benzhydryl chloride + dimethylaminoethanol.
Uses: allergy, motion sickness, insomnia, anaphylaxis adjunct, EPS.

UNIT IV

Hypoglycaemic, Anti-thyroid Drugs, Sulphonamides & Quinolones (10 h)

Classify oral hypoglycaemic agents 🔊. Discuss the SAR of sulphonylureas and the synthesis of tolbutamide 🔊.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINEType-2 diabetes — affecting 500+ million people — is managed by a growing armoury of oral drugs; the sulphonylureas that dominated therapy for half a century now share the stage with metformin, DPP-4 inhibitors, SGLT-2 inhibitors and others.

Classification:

Class	Examples	Mechanism
Sulphonylureas — 1st gen	Tolbutamide, chlorpropamide, tolazamide	Block β-cell K-ATP channel → ↑ insulin release
Sulphonylureas — 2nd gen	Glibenclamide (glyburide), glipizide, gliclazide, glimepiride	Same, more potent
Meglitinides (glinides)	Repaglinide, nateglinide	Short-acting K-ATP blockers
Biguanides	Metformin, phenformin (withdrawn)	↓ hepatic gluconeogenesis, ↑ insulin sensitivity
Thiazolidinediones (glitazones)	Pioglitazone, rosiglitazone (restricted)	PPAR-γ agonist
α-Glucosidase inhibitors	Acarbose, miglitol, voglibose	Delay carbohydrate digestion
DPP-4 inhibitors (gliptins)	Sitagliptin, saxagliptin, linagliptin, vildagliptin	↑ GLP-1
GLP-1 analogues	Exenatide, liraglutide, dulaglutide, semaglutide	↑ insulin, ↓ glucagon, ↓ appetite
SGLT-2 inhibitors	Dapagliflozin, canagliflozin, empagliflozin	↓ renal glucose reabsorption
Amylin analogue	Pramlintide	↓ glucagon, ↓ gastric emptying
Dopamine agonist (low-dose)	Bromocriptine	Central insulin sensitisation

SAR of Sulphonylureas:
Core structure: Ar-SO₂-NH-CO-NH-R (sulphonyl-urea).
(1) Aryl sulphonyl group — essential; p-substituent on benzene (CH₃ in tolbutamide, Cl in chlorpropamide, acetyl in acetohexamide) increases activity.
(2) Sulphonamide linkage (-SO₂-NH-) — cannot be modified without loss of activity.
(3) Urea bridge (-CO-NH-) — essential.
(4) N'-substituent (R) — aliphatic or cyclic: - Short alkyl (butyl, propyl) — first-generation (tolbutamide, chlorpropamide); - Cyclohexyl or larger aralkyl — second-generation (glibenclamide, glipizide) — more potent (100 × tolbutamide).
(5) Second-generation sulphonylureas have an additional para-substituted aryl-carboxamide group connected via ethyl linker to the urea nitrogen — increases receptor affinity.

Synthesis of Tolbutamide:
Step 1: p-Toluenesulphonamide + n-butyl isocyanate → 1-butyl-3-(4-methylbenzenesulphonyl)-urea (tolbutamide) Alternative: p-toluenesulphonyl chloride + ammonia → sulphonamide; then with n-butylamine → butyl-carbamoyl-sulphonamide via intermediate chloride. Mp 126–132 °C; white crystalline powder; slightly soluble in water, soluble in alkali.

Pharmacological Profile of Sulphonylureas:
Mechanism: Bind SUR1 subunit of β-cell K-ATP channel → close channel → depolarise β-cell → Ca²⁺ influx → exocytosis of insulin granules.
Uses: Type-2 DM (patients with residual β-cell function); neonatal diabetes (if KCNJ11 mutation).
ADR: Hypoglycaemia (the main danger; glibenclamide > glipizide, chlorpropamide — long-acting; especially in elderly, renal failure), weight gain, rash, cholestatic jaundice, disulfiram-like reaction (chlorpropamide), SIADH (chlorpropamide), hyponatraemia.

⚡ AT-A-GLANCE SUMMARY

Oral antidiabetics: sulphonylureas, biguanides, glitazones, α-glucosidase inhibitors, DPP-4/GLP-1, SGLT-2.
Sulphonylurea SAR: Ar-SO₂-NH-CO-NH-R; aryl p-substituent + alkyl/cyclic R; 2nd gen add ary-CONH spacer.
Tolbutamide = p-CH₃-C₆H₄-SO₂-NH-CO-NH-n-Bu; from p-toluenesulphonamide + n-butyl isocyanate.
Mechanism: close K-ATP on β-cell → insulin release.
ADR: hypoglycaemia (main), weight gain, disulfiram-like (chlorpropamide).

Classify insulins 🔊. Discuss the chemistry, types and uses of insulin.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEThe 1921 isolation of insulin by Banting, Best, Collip and Macleod transformed diabetes from a death sentence into a manageable disease; a century later, the array of modern human-analogue insulins offers unprecedented glycaemic control.

Chemistry of Insulin:
Polypeptide hormone of 51 amino acids in two chains — chain A (21 residues) and chain B (30 residues) — linked by two interchain disulphide bridges (A7-B7, A20-B19) plus one intrachain disulphide (A6-A11). MW ≈ 5808 Da. Biosynthesised from pre-proinsulin → proinsulin; C-peptide is cleaved, giving mature insulin (mature dimer/hexamer coordinated by Zn²⁺ in β-granules).
Species differences: porcine insulin differs from human by one amino acid (B30 Ala); bovine differs by three. Recombinant human insulin is identical to native human insulin.

Classification of Insulin Preparations:

Type	Onset	Peak	Duration	Examples
Rapid-acting (analogue)	5–15 min	30–90 min	3–5 h	Insulin lispro, aspart, glulisine
Short-acting (regular)	30 min	2–4 h	6–8 h	Regular (soluble) human insulin
Intermediate-acting	1–2 h	4–12 h	12–18 h	NPH (isophane; insulin + protamine), insulin zinc suspension
Long-acting (analogue)	2 h	Peakless	18–24 h	Insulin glargine, detemir
Ultra-long-acting	2–4 h	Peakless	42 h	Insulin degludec
Premixed	Combinations of rapid + NPH (30/70, 25/75)			Mixtard, Humalog Mix, NovoMix

Analogues — Structural Modifications:
Lispro: reverse of proline-B28 and lysine-B29 → rapid dimer dissociation → rapid action.
Aspart: proline-B28 → aspartate.
Glulisine: asparagine-B3 → lysine; lysine-B29 → glutamate.
Glargine: asparagine-A21 → glycine; add two arginines at B30-B32 → isoelectric point shifted to 7 → precipitates at physiological pH and dissolves slowly from SC depot → 24-h action.
Detemir: threonine-B30 removed; C14 fatty acid (myristic acid) added to B29 lysine → binds albumin → long duration.
Degludec: B30 removed + C16 fatty diacid chain → multi-hexamer formation at SC site → slow dissociation → 42-h action.

Therapeutic Uses:
(1) Type-1 DM (absolute indication); (2) Type-2 DM (when oral agents fail or during stress — infection, surgery, pregnancy); (3) Diabetic ketoacidosis and hyperosmolar state (IV regular); (4) Gestational diabetes; (5) Hyperkalaemia (with glucose); (6) Critically-ill hyperglycaemic patients.

Delivery:
SC injection (pen, syringe, pump); IV only regular insulin; inhalation (Afrezza — rapid-acting); jet injectors; continuous SC infusion (insulin pump with regular or rapid-acting).
Storage: 2–8 °C (unopened vials); in-use vials stable 4 weeks at room temperature.

Adverse Effects:
Hypoglycaemia (main); lipohypertrophy and lipoatrophy at injection sites (rotate sites); weight gain; local allergy; rarely systemic allergy; insulin resistance.

⚡ AT-A-GLANCE SUMMARY

Insulin: 51-aa peptide in 2 chains (A and B) with 3 disulphide bridges.
Types by duration: rapid (lispro, aspart), short (regular), intermediate (NPH), long (glargine, detemir), ultra-long (degludec), premixed.
Analogues: lispro (B28-B29 swap), glargine (shifted pI), detemir / degludec (fatty-acid chain → albumin/hexamer binding).
Uses: T1DM (essential), T2DM (when orals fail), DKA, HHS, gestational DM.
ADR: hypoglycaemia, lipohypertrophy, weight gain.

Classify sulphonamides 🔊. Discuss their SAR and the synthesis of sulphadiazine 🔊.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEWith the 1932 discovery of prontosil by Domagk, sulphonamides ushered in the era of modern chemotherapy; though penicillins later took centre stage, sulphonamides remain pharmacologically and historically indispensable.

Classification:

Subclass	Examples	Duration / use
Short-acting	Sulphisoxazole, sulphamethizole	UTI
Medium-acting	Sulphadiazine, sulphamethoxazole	UTI, chronic infection, cotrimoxazole
Long-acting	Sulphadoxine, sulphalene	Malaria (with pyrimethamine)
Poorly absorbed (local GI)	Sulphasalazine, phthalylsulphathiazole, succinyl-sulphathiazole	IBD, preoperative gut decontamination
Topical	Silver sulphadiazine, mafenide, sulphacetamide (eye)	Burns, ophthalmic
Sulphones	Dapsone	Leprosy, dermatitis herpetiformis

Mechanism:
Structural analogues of p-aminobenzoic acid (PABA); competitively inhibit dihydropteroate synthase → block synthesis of dihydrofolate → ↓ tetrahydrofolate → ↓ nucleic-acid synthesis → bacteriostasis. When combined with trimethoprim (which inhibits dihydrofolate reductase), sequential blockade gives bactericidal synergy (cotrimoxazole).

SAR of Sulphonamides:
Parent scaffold: 4-aminobenzenesulphonamide.
(1) p-Amino group (N4) — essential; must be free (unsubstituted); if masked (as in prontosil → sulphanilamide after reduction; sulphasalazine → 5-ASA + sulphapyridine after bacterial azoreductase), activity is only after release; acetylation in vivo inactivates.
(2) Sulphonamide group (-SO₂NH₂) — essential; replacement by -CONH- abolishes activity.
(3) N1-substituent (R) — modifies pKa, potency and duration; heterocyclic substituents (pyrimidine in sulphadiazine, oxazole in sulphamethoxazole, isoxazole in sulphisoxazole) give a pKa around 7 (50 % ionised at physiological pH — best balance of absorption and antibacterial activity).
(4) Benzene ring must be intact and unsubstituted; para-substitution is mandatory (isomerism shifts activity).

Synthesis of Sulphadiazine:
Step 1: Acetanilide + chlorosulphonic acid → p-acetamidobenzene-sulphonyl chloride (ASC) Step 2: ASC + 2-aminopyrimidine → N⁴-acetyl-sulphadiazine Step 3: Alkaline hydrolysis (NaOH / HCl) → sulphadiazine (N¹-(pyrimidin-2-yl)-sulphanilamide) White crystalline powder; practically insoluble in water (hence crystalluria risk); soluble in alkali (sodium salt is used IV); mp 252-256 °C.

Uses & ADR:
Sulphadiazine — toxoplasmosis (with pyrimethamine), nocardiosis, meningococcal prophylaxis; silver sulphadiazine 1 % cream — burn-wound infection prevention. Sulphamethoxazole (with trimethoprim = cotrimoxazole) — UTI, PCP (Pneumocystis jiroveci), toxoplasmosis, shigellosis.
ADR: hypersensitivity rash (common), Stevens-Johnson syndrome, crystalluria (alkalinise urine and ensure hydration), haemolytic anaemia in G6PD deficiency, aplastic anaemia, kernicterus in neonates (displace bilirubin), hepatotoxicity, nephrotoxicity.

⚡ AT-A-GLANCE SUMMARY

Sulphonamides: PABA analogues → inhibit dihydropteroate synthase → ↓ folate.
Subclasses by duration (short/medium/long), poorly absorbed (GI), topical, sulphones.
SAR: p-NH₂ + Ar-SO₂-NH-R; free N4 essential; N1-heterocycle (pyrimidine, isoxazole) for optimal pKa.
Sulphadiazine: acetanilide → chlorosulphonation → + 2-aminopyrimidine → hydrolysis.
Uses: toxoplasmosis, burns (Ag salt); ADR: rash, SJS, crystalluria, haemolysis (G6PD), kernicterus.

Classify quinolones 🔊 with examples. Discuss the SAR of fluoroquinolones and the synthesis of ciprofloxacin 🔊.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEFrom nalidixic acid (1962) to the modern fluoroquinolones, the quinolones have become a mainstay of outpatient and hospital infections — ciprofloxacin, introduced in 1983, remains one of the most widely prescribed antibiotics in history.

Classification:

Generation	Examples	Spectrum / use
1st generation (quinolones)	Nalidixic acid, cinoxacin, oxolinic acid	Gram-negative UTI
2nd generation (fluoroquinolones)	Ciprofloxacin, norfloxacin, ofloxacin, pefloxacin, lomefloxacin	Broader Gram-negative + some Gram-positive, UTI, respiratory, GI
3rd generation	Levofloxacin, sparfloxacin, gatifloxacin	Better Gram-positive and atypical coverage (respiratory FQs)
4th generation	Moxifloxacin, gemifloxacin, trovafloxacin (withdrawn)	Broad + anaerobes

Mechanism of Action:
Inhibit bacterial DNA gyrase (topoisomerase II) — mainly in Gram-negatives, and topoisomerase IV — mainly in Gram-positives. Prevent DNA supercoiling and decatenation required for replication → bactericidal.

SAR of Fluoroquinolones:
Core: 4-quinolone-3-carboxylic acid.
(1) 4-Oxo and 3-COOH — essential pharmacophore (chelates Mg²⁺ in DNA-gyrase active site).
(2) N-1 substituent — cyclopropyl (ciprofloxacin) or ethyl (nalidixic); cyclopropyl increases potency and broadens spectrum.
(3) C-5 substituent — H (most); NH₂ (sparfloxacin) or CH₃ (grepafloxacin) improves anaerobic and Gram-positive activity.
(4) C-6 fluorine — hallmark of fluoroquinolones; 10- to 100-fold ↑ DNA-gyrase binding.
(5) C-7 substituent — heterocyclic amine (piperazine in ciprofloxacin / norfloxacin; methylpiperazine in ofloxacin / levofloxacin; pyrrolidine in trovafloxacin) — governs tissue penetration, spectrum and side-effect profile.
(6) C-8 substituent — F, OMe (gatifloxacin, moxifloxacin) extends activity against anaerobes but ↑ phototoxicity.
(7) Other ring fusions (oxazolo, benzo) can modify pharmacokinetics.

Synthesis of Ciprofloxacin (Gould-Jacobs type):
Step 1: 3-Chloro-4-fluoroaniline + diethyl ethoxymethylenemalonate (EMME) → enamine ester Step 2: Thermal cyclisation (250 °C in diphenyl ether) → 7-chloro-6-fluoro-4-oxoquinoline-3-carboxylate Step 3: N-alkylation with cyclopropyl bromide / base → 1-cyclopropyl-7-chloro-6-fluoro-4-oxoquinoline-3-carboxylate Step 4: Nucleophilic displacement of 7-Cl with piperazine → 1-cyclopropyl-6-fluoro-7-(piperazin-1-yl)-4-oxoquinoline-3-carboxylate Step 5: Ester hydrolysis with NaOH → ciprofloxacin (free acid; marketed as HCl)

Pharmacokinetics & Uses:
Ciprofloxacin — oral bioavailability 70 %; impaired by antacids and di-/tri-valent cations (chelates); t_{1/2} 4 h; mainly renal excretion.
Uses: UTI (complicated, pyelonephritis), typhoid, shigellosis, traveller's diarrhoea, anthrax prophylaxis, bone/joint infections, Gram-negative septicaemia, corneal ulcer, ophthalmic/otic drops.
ADR: GI upset, CNS (headache, dizziness, seizures), tendinitis and Achilles-tendon rupture (especially with steroids), photosensitivity, QT prolongation (moxifloxacin worst), C. difficile colitis, arthropathy in young (< 18 y), dysglycaemia, aortic dissection risk.

⚡ AT-A-GLANCE SUMMARY

Four generations of quinolones; 2nd-gen fluoroquinolones (ciprofloxacin) onwards have C-6 fluorine.
Mechanism: inhibit DNA gyrase + topoisomerase IV → bactericidal.
SAR: 4-oxo + 3-COOH pharmacophore; N-1 cyclopropyl; C-6 F; C-7 piperazine (Cipro) or methylpiperazine; C-8 OMe for anaerobes.
Ciprofloxacin: from 3-chloro-4-fluoroaniline + EMME → thermal cyclisation → N-cyclopropylation → piperazine → hydrolysis.
ADR: tendinitis, QT prolongation, photosensitivity, C. difficile, dysglycaemia.

UNIT V

Antitubercular, Antifungal, Antiviral & Antineoplastic Drugs (6 h)

Classify antitubercular drugs. Discuss the pharmacology of isoniazid 🔊 and give its synthesis.

★★★★★

10MLong Essay

Detailed Answer:

✍️ OPENING LINETuberculosis still infects ~10 million people and kills 1.5 million each year; modern antitubercular chemotherapy — built on the four first-line drugs INH, rifampicin, pyrazinamide and ethambutol — remains our best defence, and isoniazid the single most important component.

Classification:

Class	Drugs
First-line	Isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E), streptomycin (S)
Second-line injectables	Kanamycin, amikacin, capreomycin
Second-line oral	Ethionamide, prothionamide, cycloserine, PAS (para-aminosalicylic acid), terizidone, thiacetazone
Fluoroquinolones	Moxifloxacin, levofloxacin, gatifloxacin
New-generation	Bedaquiline (ATP-synthase inhibitor), delamanid, pretomanid, linezolid, clofazimine

Standard 6-month regimen (WHO DOTS): 2 months HRZE → 4 months HR. MDR-TB requires 9-18 months therapy including fluoroquinolones + injectable + bedaquiline.

Isoniazid — Chemistry:
Chemical name: isonicotinic acid hydrazide. Molecular formula C₆H₇N₃O; MW 137. White crystalline solid; water-soluble; mp 170 °C.

Mechanism of Action:
INH is a prodrug activated inside mycobacteria by katG-encoded catalase-peroxidase to an active species (isonicotinoyl-acyl radical or iodine) that binds to NAD⁺ to form an adduct which inhibits InhA (enoyl-ACP reductase) → blocks mycolic-acid synthesis → disruption of cell wall → bactericidal to replicating mycobacteria.
Mutations in katG cause high-level INH resistance; mutations in inhA promoter give low-level resistance.

Pharmacokinetics:
Rapidly and completely absorbed orally; peak 1-2 h; widely distributed including CSF and caseous lesions; metabolism by N-acetyltransferase-2 (NAT2) — genetic polymorphism giving "fast" (t_{1/2} 1 h) and "slow" (t_{1/2} 3 h) acetylators; majority excreted in urine as N-acetyl derivative.

Therapeutic Uses:
(1) Active pulmonary and extrapulmonary TB (part of HRZE regimen). (2) Latent TB infection (LTBI) — 300 mg daily × 6-9 months. (3) TB chemoprophylaxis in close contacts of smear-positive TB patients (especially children < 5 y), HIV, diabetics.

Synthesis of Isoniazid:
Step 1: 4-Methylpyridine (γ-picoline) + KMnO₄ (oxidation) → isonicotinic acid Step 2: Isonicotinic acid + ethanol/H₂SO₄ (esterification) → ethyl isonicotinate Step 3: Ethyl isonicotinate + hydrazine hydrate (NH₂NH₂ · H₂O) in ethanol (reflux) → isoniazid (isonicotinic acid hydrazide) + ethanol

Adverse Effects:
(1) Peripheral neuropathy — due to depletion of pyridoxine (B6); prevented by co-administration of 10-25 mg/day pyridoxine, especially in diabetics, alcoholics, pregnancy, HIV. (2) Hepatitis — risk ↑ with age, alcohol use, rifampicin; monitor LFTs. (3) Rashes, fever, lupus-like syndrome. (4) Seizures (overdose; reverse with high-dose pyridoxine). (5) Haemolytic anaemia in G6PD deficiency. (6) Increases phenytoin levels (inhibits CYP2C9, especially in slow acetylators). (7) Mental changes, optic neuritis.

⚡ AT-A-GLANCE SUMMARY

ATT: first-line HRZE + S; second-line fluoroquinolones + injectables + bedaquiline/delamanid.
Standard regimen: 2 HRZE / 4 HR; MDR-TB longer + bedaquiline.
Isoniazid: prodrug → inhibits InhA → blocks mycolic-acid synthesis.
Synthesis: γ-picoline → isonicotinic acid → ester → + NH₂NH₂ → INH.
ADR: peripheral neuropathy (give pyridoxine), hepatitis, lupus-like.

Classify antifungal drugs 🔊. Discuss the SAR of azoles and the synthesis of fluconazole 🔊.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINEFungi, with their eukaryotic biology, present a tougher target than bacteria; the azole antifungals — born in the 1960s with clotrimazole and reaching maturity with fluconazole, voriconazole and posaconazole — remain the most widely used systemic antifungals.

Classification:

Class	Examples	Target / use
Polyenes	Amphotericin B (lipid + conventional), nystatin	Bind ergosterol → pore → cell leak; systemic AmB, topical nystatin
Azoles — Imidazoles	Clotrimazole, miconazole, ketoconazole, econazole	Topical and (keto) systemic (superseded)
Azoles — Triazoles	Fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole	Systemic mycoses
Echinocandins	Caspofungin, micafungin, anidulafungin	Inhibit β-1,3-glucan synthase; Candida, Aspergillus
Allylamines	Terbinafine, naftifine	Squalene epoxidase inhibitor; dermatophytes, onychomycosis
Antimetabolites	Flucytosine (5-FC)	Candida + Cryptococcus (with AmB)
Miscellaneous	Griseofulvin, tolnaftate, ciclopirox, amorolfine, undecylenic acid	Dermatophytes

Mechanism of Azoles:
Inhibit fungal cytochrome P450 14-α-demethylase (encoded by CYP51/ERG11) → block conversion of lanosterol to ergosterol → disrupts fungal cell membrane integrity. Triazoles bind fungal enzyme with higher affinity than mammalian CYP → fewer endocrine side effects than imidazoles.

SAR of Azoles:
Structural motif: imidazole or 1,2,4-triazole nitrogen-containing five-membered ring coordinates with haem iron of fungal CYP51.
(1) Azole ring — imidazole (clotrimazole, ketoconazole, miconazole) or 1,2,4-triazole (fluconazole, voriconazole, itraconazole); triazoles more metabolically stable and selective.
(2) N-1 linker — CH₂-CHOH-CH₂ (fluconazole, itraconazole), C-O (miconazole), piperazine-dioxolane (ketoconazole).
(3) Aromatic rings — one or two substituted phenyls (usually halogenated) fit into hydrophobic pocket; 2,4-difluorophenyl (fluconazole) gives optimum activity.
(4) Stereochemistry — (R,R) or (S,R) activity differs; voriconazole is 2R,3S-stereoisomer.
(5) Two azole rings (fluconazole, posaconazole) give improved water solubility and oral bioavailability.

Synthesis of Fluconazole:
Step 1: 1,3-Dichloroacetone + 1H-1,2,4-triazole (Na salt) → 1,3-bis(1H-1,2,4-triazol-1-yl)-propan-2-one Step 2: Grignard addition of 2,4-difluorophenyl magnesium bromide (C₆H₃F₂MgBr) to the central ketone → fluconazole (2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)-propan-2-ol) White crystalline powder; mp 139 °C; freely soluble in water (unusually water-soluble for an azole).

Pharmacokinetics & Uses of Fluconazole:
Oral bioavailability > 90 %; unaffected by food; widely distributed (including CSF); mainly renal excretion; t_{1/2} 25-30 h → once-daily dosing.
Uses: oropharyngeal and oesophageal candidiasis, vaginal candidiasis (single 150 mg dose), candidaemia, cryptococcal meningitis (maintenance after IV amphotericin B), coccidioidomycosis, prophylaxis in neutropenic patients.
ADR: GI upset, headache, transaminitis, rash, QT prolongation (moderate; less than ketoconazole), CYP3A4 and CYP2C9 inhibition → significant interactions with warfarin, phenytoin, sulphonylureas, tacrolimus, statins.
Teratogenicity with high-dose (limit in pregnancy to single 150 mg for candidiasis).

⚡ AT-A-GLANCE SUMMARY

Antifungals: polyenes (AmB), azoles (imidazoles + triazoles), echinocandins, allylamines, antimetabolites.
Azoles inhibit fungal CYP51 (14-α-demethylase) → block ergosterol synthesis.
SAR: imidazole or triazole + CH₂-linker + halogenated aromatic ring; triazoles selective.
Fluconazole: 1,3-dichloroacetone → 2 × triazole → Grignard with 2,4-difluorophenyl.
Uses: candidiasis, cryptococcal meningitis; ADR: LFT↑, QT, many CYP interactions.

Classify antineoplastic drugs 🔊 with examples. Briefly discuss the mechanism and uses of cyclophosphamide 🔊.

★★★★☆

10MLong Essay

Detailed Answer:

✍️ OPENING LINECancer chemotherapy has evolved dramatically from the serendipitous use of nitrogen mustard in 1942 to today's targeted biologics; cyclophosphamide, an early alkylating agent, remains a cornerstone of many modern regimens thanks to its favourable therapeutic index.

Classification:

Class	Examples
Alkylating agents — nitrogen mustards	Mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil
Alkylating — others	Nitrosoureas (carmustine, lomustine), busulfan, dacarbazine, temozolomide, procarbazine, mitomycin
Platinum compounds	Cisplatin, carboplatin, oxaliplatin
Antimetabolites — folate	Methotrexate, pemetrexed
Antimetabolites — purine	6-Mercaptopurine, 6-thioguanine, fludarabine, cladribine
Antimetabolites — pyrimidine	5-Fluorouracil, capecitabine, cytarabine, gemcitabine
Antitumour antibiotics	Doxorubicin, daunorubicin, bleomycin, mitomycin C, actinomycin-D
Plant-derived — Vinca alkaloids	Vincristine, vinblastine, vinorelbine
Plant-derived — Taxanes	Paclitaxel, docetaxel, cabazitaxel
Plant-derived — Topoisomerase inhibitors	Etoposide, teniposide (II); topotecan, irinotecan (I)
Hormones & antagonists	Prednisolone, tamoxifen, anastrozole, flutamide, leuprorelin, raloxifene
Targeted therapies — small molecules	Imatinib, erlotinib, gefitinib, sorafenib, sunitinib, ibrutinib, venetoclax
Targeted therapies — monoclonal antibodies	Trastuzumab, rituximab, bevacizumab, cetuximab, alemtuzumab
Immunotherapies (checkpoint inhibitors)	Pembrolizumab, nivolumab, ipilimumab, atezolizumab
Miscellaneous	L-asparaginase, hydroxyurea, all-trans retinoic acid, arsenic trioxide

Cyclophosphamide — Chemistry:
N,N-bis(2-chloroethyl)phosphorodiamide cyclic ester. White crystalline; soluble in water; mp 49–53 °C. Marketed as the monohydrate; administered oral or IV.

Mechanism:
Cyclophosphamide is a prodrug. In the liver, CYP2B6 hydroxylates it to 4-hydroxycyclophosphamide → tautomerises to aldophosphamide → spontaneously gives phosphoramide mustard (the active alkylator) + acrolein (urotoxic metabolite).
Phosphoramide mustard forms reactive aziridinium intermediates that alkylate the N-7 position of guanine in DNA → intra- and inter-strand cross-links → DNA strand breaks → apoptosis. Cell-cycle non-specific.

Pharmacokinetics:
Oral bioavailability > 75 %; t_{1/2} 4–8 h; peak of active metabolites 2–3 h; renal and hepatic excretion. Inactivation of the prodrug is irreversible once cleaved.

Therapeutic Uses:
(1) Haematological malignancies — non-Hodgkin and Hodgkin lymphoma (CHOP regimen), chronic lymphocytic leukaemia, multiple myeloma. (2) Solid tumours — breast cancer (CMF regimen), ovarian cancer, small-cell lung cancer, Ewing's sarcoma, neuroblastoma. (3) Conditioning regimen before bone-marrow transplant. (4) Immunosuppressive — severe rheumatoid arthritis, SLE nephritis, Wegener's granulomatosis, multiple sclerosis.

Adverse Effects:
Haemorrhagic cystitis — due to acrolein; prevented by adequate hydration and co-administration of MESNA (mercapto-ethane-sulphonate) which binds acrolein in urine.
Myelosuppression (main dose-limiting toxicity), nausea/vomiting, alopecia, cardiotoxicity (high dose BMT conditioning), infertility, teratogenicity, SIADH, secondary malignancies (bladder cancer, leukaemia).

⚡ AT-A-GLANCE SUMMARY

Antineoplastics: alkylating, antimetabolites, antibiotics, plant-derived, hormones, targeted, immunotherapies.
Cyclophosphamide: prodrug → activated by hepatic CYP2B6 → phosphoramide mustard (alkylates DNA N-7 guanine) + acrolein.
Uses: NHL, CLL, breast, ovarian, SCLC, BMT conditioning, SLE nephritis, severe RA.
Unique toxicity: haemorrhagic cystitis (acrolein); prevent with hydration + MESNA.
Other ADR: myelosuppression, alopecia, SIADH, secondary cancers.

Briefly discuss diagnostic agents 🔊 used in radiology (contrast media). Give examples.

★★★☆☆

5MShort Essay

Detailed Answer:

✍️ OPENING LINEFrom the first barium-meal X-ray in 1910 to today's multi-detector CT angiography, radiological imaging depends on diagnostic contrast agents that render tissues and vessels visible to the radiation beam.

Classification:

Imaging modality	Agent	Use
X-ray & CT — positive contrast	Barium sulphate (GI), iodinated contrast (iohexol, iopamidol, iodixanol, diatrizoate, metrizamide)	GI, urography, angiography, CT scan
X-ray — negative contrast	Air, CO₂	Double-contrast GI studies
MRI	Gadolinium chelates (gadopentetate, gadobenate, gadoxetic acid); SPIO, USPIO	T1 and T2 contrast
Ultrasound	Microbubbles (SonoVue — sulphur hexafluoride; Definity — octafluoropropane)	Echocardiography, abdominal imaging
Nuclear medicine	Technetium-99m (SPECT), fluorine-18 FDG (PET), iodine-131, gallium-68, lutetium-177, radium-223	Scintigraphy, PET scan, therapy
Fluorescent / dye	Indocyanine green, fluorescein, methylene blue, evans blue	Ophthalmic angiography, liver function, lymphatic mapping

Iodinated Contrast Media:
Based on tri-iodobenzene ring. Two broad classes:
(1) Ionic (high osmolar) — diatrizoate, iothalamate; cheap but ↑ risk of contrast reactions and nephrotoxicity.
(2) Non-ionic (low/iso-osmolar) — iohexol (Omnipaque), iopamidol, iodixanol (iso-osmolar); safer and more widely used.
Mechanism: iodine atoms absorb X-rays (atomic number 53) → opacification of vessels and renal collecting system.
ADR: allergic-like reactions (prick skin reaction, urticaria, anaphylaxis), contrast-induced nephropathy (CIN — especially in dehydrated/diabetic patients; prevent by hydration + N-acetylcysteine), thyroid dysfunction (free iodine uptake), extravasation injury.

Barium Sulphate:
Insoluble, heavy white powder suspended in water flavoured with aromatic oils. Opacifies the GI tract for oesophago-gastro-duodenography and barium enema. Contraindicated if perforation suspected (use water-soluble iodinated contrast instead — gastrografin).

Gadolinium Chelates (MRI):
Gadolinium is paramagnetic and shortens T1 relaxation, producing bright signal. Administered as chelates to reduce toxicity (Gd³⁺ free is highly toxic) — gadopentetate, gadobutrol, gadobenate, gadoxetate. ADR: nephrogenic systemic fibrosis in patients with severe renal impairment; caution in GFR < 30 mL/min.

Radiopharmaceuticals:
99m-Tc (t_{1/2} 6 h, gamma emitter) — the workhorse of SPECT; used as Tc-MDP (bone scan), Tc-sestamibi (cardiac), Tc-pertechnetate (thyroid, salivary), Tc-DTPA (renal).
18-F-FDG (fluoro-deoxy-glucose) — for PET; detects metabolically active tumours, myocardial viability.
131-I — therapeutic for hyperthyroidism and thyroid cancer.
223-Ra, 177-Lu-DOTATATE, 177-Lu-PSMA — targeted therapies for bone metastases, neuroendocrine and prostate cancers (theranostics).

⚡ AT-A-GLANCE SUMMARY

Contrast media: iodinated (X-ray/CT — iohexol), barium sulphate (GI), gadolinium (MRI), microbubbles (ultrasound), 99mTc / 18-FDG (nuclear), dyes (fluorescein, ICG).
Iodinated: ionic vs non-ionic (iohexol, iodixanol); ADR allergy, contrast-induced nephropathy, thyroid issues.
Barium contraindicated if perforation suspected.
Gadolinium causes nephrogenic systemic fibrosis in severe renal impairment.
99mTc = SPECT workhorse; 18F-FDG = PET; 131I and 177Lu = therapeutic radionuclides.

Classify anti-leprosy drugs 🔊. Discuss the SAR, synthesis and mechanism of action of dapsone.

★★★☆☆

5MShort EssayPast papers: AKTU 2022; RGUHS 2021

Detailed Answer:

✍️ OPENING LINEDapsone (1908) preceded the sulphonamide era — but it took Muir (1941) to rediscover it as the sheet anchor of leprosy therapy; today WHO MDT using rifampicin + dapsone + clofazimine has cured > 16 million patients.

Classification of Anti-leprosy Drugs:

Class	Drug	Role
Sulphones	Dapsone (DDS — 4,4'-diaminodiphenyl sulphone)	First-line, bacteriostatic to M. leprae
Rifamycins	Rifampicin	Most rapidly bactericidal; kills 99.9 % bacilli after 1 dose
Phenazine dye	Clofazimine	Bactericidal + anti-inflammatory; inhibits ENL reaction
Other	Ofloxacin, minocycline, clarithromycin, thalidomide (ENL)	Alternative / adjunct

WHO-MDT (2022): 6 months for PB (paucibacillary, < 5 lesions); 12 months for MB (multibacillary, ≥ 5 lesions); all get rifampicin + dapsone; MB gets clofazimine in addition.

Dapsone (DDS) — SAR:
• Structure — two para-aminophenyl groups linked by a sulphonyl (-SO₂-) bridge; resembles para-aminobenzoic acid (PABA); belongs to sulphones;
• Both 4-NH₂ groups essential; N-substitution abolishes activity but pro-drugs (acedapsone) act as depot forms;
• Sulphonyl linker must be intact — sulphoxide / sulphide analogues are inactive;
• Aromatic rings essential.

Synthesis of Dapsone:
Route — condensation of chlorobenzene + sulphur trioxide followed by nitration and reduction:
(1) Chlorobenzene + fuming H₂SO₄ → 4,4'-dichlorodiphenyl sulphone;
(2) Nitration (HNO₃/H₂SO₄) → 4,4'-dinitro-diphenyl sulphone;
(3) Catalytic reduction (Fe/HCl or H₂/Pd) → 4,4'-diamino-diphenyl sulphone (dapsone).

Mechanism of Action:
Competitively inhibits bacterial dihydropteroate synthase (DHPS) — same target as sulphonamides — blocking incorporation of PABA into folic acid → blocks nucleic-acid synthesis in M. leprae. Also exerts anti-inflammatory action (inhibits neutrophil myeloperoxidase) useful in dermatitis herpetiformis.
Uses: leprosy (MDT), dermatitis herpetiformis, PCP (with trimethoprim), malaria prophylaxis (combo with pyrimethamine).
ADR: haemolytic anaemia (especially G6PD deficient), methaemoglobinaemia, agranulocytosis, dapsone-hypersensitivity syndrome (DRESS), peripheral neuritis, hepatitis.

⚡ AT-A-GLANCE SUMMARY

Anti-leprosy classes: sulphones (dapsone), rifamycins (rifampicin — most bactericidal), phenazine (clofazimine).
WHO-MDT — PB: R + D × 6 mo; MB: R + D + C × 12 mo.
Dapsone = 4,4'-DDS (sulphonyl-bridged diaminodiphenyl).
Synthesis — chlorobenzene → sulphone → dinitro → reduce to diamino.
MoA: inhibits DHPS (PABA antagonism) → blocks folate.
ADR — haemolysis (G6PD), methaemoglobin, DRESS.

Classify anti-gout drugs 🔊. Discuss the SAR and mechanism of action of allopurinol and colchicine.

★★★☆☆

5MShort EssayPast papers: AKTU 2021; RGUHS 2022

Detailed Answer:

✍️ OPENING LINEGout — once the "disease of kings" (Henry VIII, Benjamin Franklin) — is now a treatable metabolic disorder; colchicine calms the acute flare, allopurinol (Elion & Hitchings, 1963, Nobel 1988) prevents the next one.

Classification of Anti-gout Drugs:

Phase	Class	Examples
Acute gout	NSAIDs	Indomethacin, naproxen, diclofenac, etoricoxib
	Tubulin inhibitor	Colchicine
	Steroids	Prednisolone, triamcinolone (intra-articular)
Chronic (prophylaxis)	Xanthine oxidase inhibitors	Allopurinol, febuxostat
	Uricosurics	Probenecid, sulphinpyrazone, benzbromarone, lesinurad
	Uricase (recombinant)	Rasburicase (tumour lysis), pegloticase (refractory)
Newer biologics	IL-1β blockers	Anakinra, canakinumab (refractory acute gout)

Allopurinol — Structure & SAR:
• Structure — pyrazolo[3,4-d]pyrimidine isomer of hypoxanthine (C-8 and N-7 interchanged);
• The 4-OH tautomer is essential;
• Active metabolite = oxypurinol (alloxanthine) — has longer t½ (18-30 h vs allopurinol 1-2 h) → once-daily dosing;
• Replacement of 4-oxo with thio, amino reduces activity;
• Linking with ribose gives azathioprine analogues (not anti-gout).

Allopurinol — Mechanism:
Competitive inhibitor of xanthine oxidase (XO) — the enzyme that converts hypoxanthine → xanthine → uric acid. Active metabolite oxypurinol is a suicide substrate that binds to reduced Mo-atom of XO irreversibly. Net effect — ↓ uric acid production and ↑ solubility (xanthine more soluble than urate).
Uses: chronic gout, tophi, uric-acid kidney stones, tumour lysis syndrome, Lesch-Nyhan syndrome.
ADR: rash (2 %), hepatitis, nephritis, Stevens-Johnson (HLA-B*58:01 screening in Asians), interactions — potentiates 6-MP / azathioprine (reduce dose by 75 %).

Colchicine — Structure & SAR:
• Tricyclic alkaloid from Colchicum autumnale (autumn crocus); used since 1500 BC;
• Three fused 7-7-7-membered rings (A + B + C); methoxy groups on A-ring; N-acetyl & tropolone on C-ring essential;
• Hydrolysis of the tropolone or demethylation abolishes activity.

Colchicine — Mechanism:
Binds α,β-tubulin dimer → prevents microtubule polymerisation → inhibits leukocyte migration, phagocytosis and IL-1β release; stops the neutrophil-driven inflammatory cascade of acute gout.
Uses: acute gout (within 24-36 h of onset); prophylaxis when starting urate-lowering therapy; Familial Mediterranean Fever; Behçet's syndrome; pericarditis.
ADR: GI (diarrhoea, cramps — first sign of toxicity); bone-marrow suppression, alopecia, neuromyopathy; narrow TI — fatal overdose; CYP3A4 + P-gp substrate — interactions with macrolides, azoles, statins.

⚡ AT-A-GLANCE SUMMARY

Acute gout — NSAIDs, colchicine, steroids.
Chronic — allopurinol, febuxostat (XO-inhibitors); probenecid, sulphinpyrazone (uricosuric); rasburicase/pegloticase (uricase).
Allopurinol — pyrazolo-pyrimidine, XO inhibitor; active metabolite oxypurinol; reduce 6-MP/azathioprine dose 75 %; SJS in HLA-B*58:01.
Colchicine — tubulin binder; inhibits neutrophil migration & IL-1β; narrow TI; GI toxicity; CYP3A4/P-gp interactions.

🎯 EXAM TIPS & STRATEGIES FOR BP501T

Start every medicinal-chemistry essay with a classification table — makes long answers structured and easy to mark.
SAR + synthesis + uses + ADR is the expected structure for every drug class (cyclophosphamide, atorvastatin, ciprofloxacin, etc.).
Give the chemical name of the key drug in each class (captopril = 1-[3-mercapto-2-methylpropanoyl]-L-proline).
Memorise Vaughan-Williams antiarrhythmic classes and examples of each.
Diuretic classes by site (PCT-TAL-DCT-CD) is a high-yield diagram.
Always draw the synthesis scheme for big drugs: captopril, nifedipine (Hantzsch), procainamide, HCTZ, tolbutamide, sulphadiazine, ciprofloxacin (Gould-Jacobs), fluconazole, isoniazid, diphenhydramine.
Narrow-TI drugs: digoxin, warfarin, lithium, phenytoin — therapeutic drug monitoring matters.
Antidotes: warfarin → vitamin K / FFP / PCC; digoxin → DigiFab; cyclophosphamide (urotoxicity) → MESNA.
Structure-activity triangle: ring system + pharmacophore + side chain — always identify these for SAR questions.
Hormone replacement: insulin analogue modifications (glargine, detemir, degludec) are frequent short-essay topics.

KMR ADVICE

EXAM STRATEGY & IMPORTANT QUESTIONS GUIDE

5.1 BP501T · MEDICINAL CHEMISTRY II (THEORY)

📖 HOW TO USE THIS GUIDE

📋 PCI SYLLABUS COVERAGE CHECKLIST — BP501T (45 h)

📊 PAST-PAPER FREQUENCY ANALYSIS (2019–2023)

PRIORITY READING GUIDE

🎯 EXAM TIPS & STRATEGIES FOR BP501T

📷 DIAGRAMS TO DRAW / INSERT — BP501T

🔄 QUICK-REFERENCE FLOWCHARTS — BP501T

🎯 CAREER GUIDANCE — Where Does BP501T Take You?

🇮🇳 1. Quality Control (QC) Analyst — Pharmaceutical Industry

Role + Responsibilities

🇮🇳 2. Quality Assurance (QA) Officer

Role + Responsibilities

🇮🇳 3. Analytical R&D / Formulation Scientist

Role + Responsibilities

🇮🇳 4. Regulatory Affairs (RA) Officer

Role + Responsibilities

🇮🇳 5. Production / Manufacturing Officer

Role + Responsibilities

🇮🇳 6. Hospital / Clinical Pharmacist (Pharm.D-led)

Role + Responsibilities

🇮🇳 7. Pharmacovigilance (PV) Specialist

Role + Responsibilities

🇮🇳 8. Drug Inspector (Govt. — Gazetted Officer)

Role + Responsibilities

🇮🇳 9. Medical Writer / Regulatory Writer

Role + Responsibilities

🇮🇳 10. Community Pharmacist / Janaushadhi Owner (PMBJP)

Role + Responsibilities

🇮🇳 11. Academic / Teaching Faculty

Role + Responsibilities

🇮🇳 12. Higher Studies — M.Pharm / Pharm.D / PhD

Role + Responsibilities

🌍 INTERNATIONAL CAREER MARKETS

📜 STRATEGIC CERTIFICATIONS & SKILLS — 5-Year Action Plan

Year 1 (Final-year B.Pharm + first job)

Year 2-3 (Junior roles → consolidation)

Year 4-5 (Mid-career specialisation)

Software / Tools to Master (Subject-Generic)

Languages & Communication

🧠 Knowledge & Interest Self-Checker — Where Could BP501T Take You?

👨‍🏫 Authored & Developed By

Institution

Contact & Web